中华实验和临床病毒学杂志
中華實驗和臨床病毒學雜誌
중화실험화림상병독학잡지
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL VIROLOGY
2011年
1期
26-28
,共3页
李明慧%谢尧%邱国华%路遥%赵辉%杨民%宋淑静%刘凤%张书凤%陈利军%成军%徐道振
李明慧%謝堯%邱國華%路遙%趙輝%楊民%宋淑靜%劉鳳%張書鳳%陳利軍%成軍%徐道振
리명혜%사요%구국화%로요%조휘%양민%송숙정%류봉%장서봉%진리군%성군%서도진
肝炎,乙型,慢性%治疗结果%干扰素-α%肝炎表面抗原,乙型%肝炎e抗原,乙型%DNA
肝炎,乙型,慢性%治療結果%榦擾素-α%肝炎錶麵抗原,乙型%肝炎e抗原,乙型%DNA
간염,을형,만성%치료결과%간우소-α%간염표면항원,을형%간염e항원,을형%DNA
Hepatitis B,chronic%Treatment outcome%Interferon-alpha%Hepatitis B Surface antigens%Hepatitis B e antigens%DNA
目的 探讨HBeAg阳性慢性乙型肝炎IFN-α治疗中HBsAg、HBeAg和HBV-DNA含量变化的相关性.方法 对HBeAg阳性慢性乙型患者,在入组后进行IFN-α3MU～5MU隔日皮下注射一次的抗病毒治疗,于治疗前和治疗中的每间隔3个月收集血清,用实时荧光定量PCR进行HBV-DNA含量检测,血清HBsAg、HBeAg含量采用美国Abbott微粒化学发光法检测试剂,ARCHITECH i2000检测.HBV-DNA含量的检测下线为5×102拷贝/ml.分析IFN治疗过程中血清HBV-DNA、HBeAg和HBsAg含量变化的相关性.结果 入组患者228例,男性162例,女性66例,年龄14～60岁,平均30.94岁;治疗过程中HBV-DNA、HBeAg和HBsAg的含量均逐渐下降干扰素治疗前以及治疗期间HBsAg与HBeAg、HBsAg与HBV-DNA含量变化间无相关性(P＞0.05);而血清HBeAg与HBV-DNA含量变化相关性有统计学意义(P＜0.05);随着干扰素治疗时间的延长,HBeAg与HBV-DNA含量逐渐下降,二者变化趋势一致.结论 干扰素治疗前及治疗期间,HBeAg与HBV-DNA含量变化密切相关,而HBsAg含量变化与HBeAg和HBV-DNA含量变化无相关性,干扰素治疗期间需对三指标同时检测.
目的 探討HBeAg暘性慢性乙型肝炎IFN-α治療中HBsAg、HBeAg和HBV-DNA含量變化的相關性.方法 對HBeAg暘性慢性乙型患者,在入組後進行IFN-α3MU～5MU隔日皮下註射一次的抗病毒治療,于治療前和治療中的每間隔3箇月收集血清,用實時熒光定量PCR進行HBV-DNA含量檢測,血清HBsAg、HBeAg含量採用美國Abbott微粒化學髮光法檢測試劑,ARCHITECH i2000檢測.HBV-DNA含量的檢測下線為5×102拷貝/ml.分析IFN治療過程中血清HBV-DNA、HBeAg和HBsAg含量變化的相關性.結果 入組患者228例,男性162例,女性66例,年齡14～60歲,平均30.94歲;治療過程中HBV-DNA、HBeAg和HBsAg的含量均逐漸下降榦擾素治療前以及治療期間HBsAg與HBeAg、HBsAg與HBV-DNA含量變化間無相關性(P＞0.05);而血清HBeAg與HBV-DNA含量變化相關性有統計學意義(P＜0.05);隨著榦擾素治療時間的延長,HBeAg與HBV-DNA含量逐漸下降,二者變化趨勢一緻.結論 榦擾素治療前及治療期間,HBeAg與HBV-DNA含量變化密切相關,而HBsAg含量變化與HBeAg和HBV-DNA含量變化無相關性,榦擾素治療期間需對三指標同時檢測.
목적 탐토HBeAg양성만성을형간염IFN-α치료중HBsAg、HBeAg화HBV-DNA함량변화적상관성.방법 대HBeAg양성만성을형환자,재입조후진행IFN-α3MU～5MU격일피하주사일차적항병독치료,우치료전화치료중적매간격3개월수집혈청,용실시형광정량PCR진행HBV-DNA함량검측,혈청HBsAg、HBeAg함량채용미국Abbott미립화학발광법검측시제,ARCHITECH i2000검측.HBV-DNA함량적검측하선위5×102고패/ml.분석IFN치료과정중혈청HBV-DNA、HBeAg화HBsAg함량변화적상관성.결과 입조환자228례,남성162례,녀성66례,년령14～60세,평균30.94세;치료과정중HBV-DNA、HBeAg화HBsAg적함량균축점하강간우소치료전이급치료기간HBsAg여HBeAg、HBsAg여HBV-DNA함량변화간무상관성(P＞0.05);이혈청HBeAg여HBV-DNA함량변화상관성유통계학의의(P＜0.05);수착간우소치료시간적연장,HBeAg여HBV-DNA함량축점하강,이자변화추세일치.결론 간우소치료전급치료기간,HBeAg여HBV-DNA함량변화밀절상관,이HBsAg함량변화여HBeAg화HBV-DNA함량변화무상관성,간우소치료기간수대삼지표동시검측.
Objective To investigate the relation of serum HBsAg, HBeAg contents and HBV-DNA load changes in HBeAg-positive chronic hepatitis B during IFN-α treatment. Methods After enrolled, the patients were treated with 3MU-5MU IFN subcutaneous injection every two days, and their serum was collected before treatment and every 3 months during the treatment course. The serum HBV-DNA load was determined by real-time fluorescence quantitative PCR method kit ( lower detection limit 500 copies/ml, Piji company, Shenzhen city, China,) according to production instruction, and HBeAg and HBsAg contents were detected by ARCHITECH I 2000.chemiluminescent kit. The relation of serum HBV-DNA, HBeAg and HBsAg content was analyzed by SPSS statistic software. Results There were 228 patients enrolled into this group, male 162 cases, female 66 cases, aged 14-60 years, average 30. 94 years old. After 1FN treatment the HBV-DNA, HBeAg and HBsAg levels were all gradually decreased. But there was no relation of HBsAg content to HBV DNA and HBeAg content before and during treatment course( P ＞0.05 ). However the serum HBeAg content was related to HBV-DNA content significantly (P ＜ 0.05 ) and their changes was correspondence. Conclusion Before and during treatment of interferon, HBeAg and HBV-DNA content changes are closely related, while there is no significant correlation between HBsAg and HBeAg and HBV-DNA content. During interferon therapy, HBsAg, HBeAg, HBV-DNA contents should be detected together.
